Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan

Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Multi-center Observational Study in Taiwan

Abatacept Registry in Taiwan

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• ≥ 20 years of age
• Who give informed consent
• Confirmed diagnosis of RA (as defined by American College of Rheumatology revised 1987 criteria) and has ≥ 4 of the criteria listed below for ≥6 weeks before study enrollment
• Who self-pay or who are reimbursed by BNHI for abatacept treatment
• With latent TB or who are receiving anti-TB treatment (INH 300 mg, QD) 1 month prior to using abatacept and continuously up to a total of 9 months Willing to follow Taiwan Risk Management Plan guidelines as required by Taiwan health authorities
• Are being treated with abatacept or are abatacept treatment naïve and are initiating abatacept therapy

Exclusion Criteria:

• Pregnant or breast feeding
• With active TB
• HBsAg (+)and/or Anti-HCV(+) and/or HBV DNA(+)
• Have cancer (patients who were treated and have no sign of cancer for > 10 years can be included)
• Are allergic to abatacept
• Enrolled in other RA clinical studies